Results 41 to 50 of about 295,913 (316)

An update on methods for detection of prognostic and predictive biomarkers in melanoma

Frontiers in Cell and Developmental Biology, 2023
The approval of immunotherapy for stage II-IV melanoma has underscored the need for improved immune-based predictive and prognostic biomarkers. For resectable stage II-III patients, adjuvant immunotherapy has proven clinical benefit, yet many patients ...
Oluwaseyi Adeuyan, Emily R. Gordon, Divya Kenchappa, Yadriel Bracero, Ajay Singh, Gerardo Espinoza, Larisa J. Geskin, Yvonne M. Saenger   +7 more
doaj   +1 more source

Mathematical Prognostic Biomarker Models for Treatment Response and Survival in Epithelial Ovarian Cancer

, 2011
Following initial standard chemotherapy (platinum/taxol), more than 75% of those patients with advanced stage epithelial ovarian cancer (EOC) experience a recurrence.
Walter C. Low, Amy P.N. Skubitz, Kristin L.M. Boylan, Jason B. Nikas   +3 more
core   +1 more source

MPIC: Molecular Prognostic Indicators in Cirrhosis Database for Clinical Context-Specific in Silico Prognostic Biomarker Validation

Frontiers in Genetics, 2019
Prognostic biomarkers are vital in the management of progressive chronic diseases such as liver cirrhosis, affecting 1–2% of the global population and causing over 1 million deaths every year.
Shun H. Yip, Naoto Fujiwara, Naoto Fujiwara, Jason Burke, Anand Shetler, Celina Peralta, Tongqi Qian, Hiroki Hoshida, Shijia Zhu, Yujin Hoshida   +9 more
doaj   +1 more source

Aquaporins as Prognostic Biomarker in Prostate Cancer

, 2023
Prostate cancer is a complex heterogeneous disease that affects millions of males worldwide. Despite rapid advances in molecular biology and innovation in technology, few biomarkers have been forthcoming in prostate cancer.
Sanjay Gupta, Shiv Verma, Prem Prakash Kushwaha   +2 more
core   +1 more source

Identification of COPA as a potential prognostic biomarker and pharmacological intervention target of cervical cancer by quantitative proteomics and experimental verification

Journal of Translational Medicine, 2022
Background Cervical cancer is the most fatal gynecological carcinoma in the world. It is urgent to explore novel prognostic biomarkers and intervention targets for cervical cancer.
Huiqiong Bao, Xiaobin Li, Zhixing Cao, Zhihong Huang, Li Chen, Mingbing Wang, Jiali Hu, Wenting Li, Hongwei Sun, Xue Jiang, Ping Mei, Huawen Li, Ligong Lu, Meixiao Zhan   +13 more
doaj   +1 more source

Prediction of acute coronary syndromes by urinary proteome analysis. [PDF]

PLoS ONE, 2017
Identification of individuals who are at risk of suffering from acute coronary syndromes (ACS) may allow to introduce preventative measures. We aimed to identify ACS-related urinary peptides, that combined as a pattern can be used as prognostic biomarker.
Nay M Htun, Dianna J Magliano, Zhen-Yu Zhang, Jasmine Lyons, Thibault Petit, Esther Nkuipou-Kenfack, Adela Ramirez-Torres, Constantin von Zur Muhlen, David Maahs, Joost P Schanstra, Claudia Pontillo, Martin Pejchinovski, Janet K Snell-Bergeon, Christian Delles, Harald Mischak, Jan A Staessen, Jonathan E Shaw, Thomas Koeck, Karlheinz Peter   +18 more
doaj   +1 more source

SEMA6A is a prognostic biomarker in glioblastoma

Tumor Biology, 2015
Glioblastoma multiforme (GBM) is one of the most aggressive tumors in the central nervous system. SEMA6A, the first identified class 6 semaphorin, is contributed to regulate vascular development and adult angiogenesis. However, the function of SEMA6A in GBM is still undefined.
Jiaxin, Zhao, Haitao, Tang, Hong, Zhao, Wanli, Che, Lei, Zhang, Peng, Liang   +5 more
openaire   +2 more sources

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási, Bernadett Borbála Huszti, Gábor Barna, Marko Kavcic, Janez Jazbec, Lennart Lenk, Vera Münch, Sophia Polychronopoulou, Ágnes Márk, Maria Thastrup, Lüder H. Meyer, Kjeld Schmiegelow, Cornelia Eckert, Christina Halsey, Dániel J. Erdélyi   +14 more
wiley   +1 more source

Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. [PDF]

, 2012
BACKGROUND: Heat shock protein 27 (Hsp-27) encoded by gene HSPB1 is a critical regulator of the behavioral phenotype of human prostate cancer (PCa) cells, enhanced expression being associated with highly aggressive disease and poor clinical outcome.
M A Thorat, Beesley, C, Lorincz, AT, Y-J Lu, H Møller, Y Yu, Cuzick, J, D M Berney, Moller, Henrik; id_orcid, N Vasiljević, Ahmad, A S, C Beesley, Moller, H, J Cuzick, Lu, Y-J, Berney, DM, Foster, C S, Thorat, M A, Vasiljević, N, Ahmad, AS, Fisher, G, Møller, H, Foster, CS, A T Lorincz, Yu, Y, G Fisher, C S Foster, A S Ahmad, Lorincz, A T, Thorat, MA, Berney, D M   +30 more
core   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source